🧬 Tempus AI Beats Earnings as Cancer Testing Demand Accelerates.
Tempus AI (NASDAQ: TEM) delivered stronger-than-expected third-quarter results after surging demand for its AI-powered cancer testing business lifted revenue 23% year over year to $411.5 million. The company posted adjusted earnings of $0.07 per share, outperforming expectations for a loss, while oncology testing volumes climbed 32%.
One of the biggest growth drivers was minimal residual disease (MRD) testing, which jumped 300% to around 12,000 tests, while its Data & Applications segment grew 33% through partnerships with companies including Bristol Myers Squibb, Merck, and Moderna. Tempus also moved closer to completing its $1.5 billion acquisition of Personalis, strengthening its cancer-detection portfolio.
The company raised the lower end of its 2026 revenue forecast to $1.60–1.605 billion and reaffirmed adjusted EBITDA guidance of about $65 million. For investors, the results reinforce Tempus' position as a fast-growing AI healthcare company where expanding diagnostics and pharmaceutical partnerships remain key catalysts.
$TEM
$MRK
$MRNA
Tempus AI (NASDAQ: TEM) delivered stronger-than-expected third-quarter results after surging demand for its AI-powered cancer testing business lifted revenue 23% year over year to $411.5 million. The company posted adjusted earnings of $0.07 per share, outperforming expectations for a loss, while oncology testing volumes climbed 32%.
One of the biggest growth drivers was minimal residual disease (MRD) testing, which jumped 300% to around 12,000 tests, while its Data & Applications segment grew 33% through partnerships with companies including Bristol Myers Squibb, Merck, and Moderna. Tempus also moved closer to completing its $1.5 billion acquisition of Personalis, strengthening its cancer-detection portfolio.
The company raised the lower end of its 2026 revenue forecast to $1.60–1.605 billion and reaffirmed adjusted EBITDA guidance of about $65 million. For investors, the results reinforce Tempus' position as a fast-growing AI healthcare company where expanding diagnostics and pharmaceutical partnerships remain key catalysts.
$TEM
$MRK
$MRNA